TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02445560

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Fiber Sachet
Description: A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Fiber Sachet
Description: A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Placebo sachet
Description: A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Placebo sachet
Description: A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Placebo sachet
Description: A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study: NCT01279200

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Midcycle ultrasound + hCG injection
Description: Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary LH kits
Description: Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
Study: NCT05179512

Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium dispensing claim is used as the reference group.

Intervention type: DRUG
Intervention: salmeterol-fluticasone
Description: Salmeterol/Fluticasone dispensing claim is used as the exposure group.
Study: NCT04549389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity shockwave therapy
Description: LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity shockwave therapy
Description: LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
Study: NCT01949701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*0201restricted URLC10 peptides with adjuvant
Description: Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*0201restricted URLC10 peptides with adjuvant.
Study: NCT02667613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Hand and arm bimanual intensive therapy including lower extremities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual customary care
Study: NCT04615169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)
Description: 2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc.
Study: NCT03213314

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparameter magnetic resonance imaging
Description: LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparameter magnetic resonance imaging
Description: LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparameter magnetic resonance imaging
Description: LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparameter magnetic resonance imaging
Description: LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
Study: NCT03864276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhalation (desflurane) group
Description: Anesthesia is induced and maintained with desflurane and sufentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total intravenous (propofol) anesthesia
Description: Anesthesia is induced and maintained with propofol and sufentanil
Study: NCT01249170

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: First year program
Description: Information on group that underwent new educational program
Study: NCT03054090

Intervention type: OTHER
Group type: OTHER
Intervention: Quality Improvement Support
Description: Practices will receive a blended strategy of quality improvement facilitation to help participating practices incorporate PCOR clinical and organizational findings while building their overall practice capabilities. Primary care practices will be provided tools and training to improve the rates of screening and treatment of risk factors for heart attacks and strokes, as well as other chronic illnesses and the delivery of preventive services.
Study: NCT03620825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dehydration by sauna exposure
Description: Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
Study: NCT01249170

Intervention type: OTHER
Group type: OTHER
Intervention: Control comparison
Description: Information from group that did not undergo new first year program
Study: NCT03550248

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Together
Description: The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
Study: NCT00522860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery with absorbable sutures
Description: Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trichiasis surgery with non-absorbable sutures
Description: Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
Study: NCT04269551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV020
Description: Pharmaceutical form:solution for injection Route of administration: intravenous
Study: NCT00275080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study: NCT05015387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive non-surgical therapy
Description: Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive non-surgical therapy
Description: Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Subgingival application of collagen hydrogels with proanthocyanidins
Description: Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Collection of saliva samples
Description: For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Collection of saliva samples
Description: For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
Study: NCT00917384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ramucirumab
Description: Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Study: NCT01449838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium
Description: active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: placebo
Study: NCT02372617

Intervention type: PROCEDURE
Intervention: periacetabular osteotomy

Intervention type: PROCEDURE
Intervention: periacetabular osteotomy
Study: NCT03840629

Intervention type: OTHER
Intervention: No study intervention.

Intervention type: OTHER
Intervention: No study intervention.
Study: NCT02406664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Laparoscopic or Robot R-Y gastric bypass
Study: NCT02636309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy at work
Description: gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
Study: NCT02081963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline
Description: Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
Study: NCT03620825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
Study: NCT02399436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Healthy Snacking Campaign
Description: The school-based healthy snacking campaign includes the following activities:~* Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;~* The installation of new filtered water fountains outfitted with water-filling stations;~* The distribution of re-usable water bottles to students at participating schools; and~* A social marketing campaign to support adoption of the healthy snacks and water consumption by students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Cooking Classes
Description: Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
Study: NCT02794610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
Study: NCT03045510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
Study: NCT04576377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBlok
Description: Recombinant HA quadrivalent influenza vaccine (0.5mL Flublok®, Sanofi Pasteur) containing 180μg antigen, 45μg for each influenza strain included.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL saline placebo.
Study: NCT03444337

Intervention type: DEVICE
Intervention: Catheter Ablation
Study: NCT03923920

Intervention type: PROCEDURE
Intervention: Biopsy
Description: During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
Study: NCT01901562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ductoscopic papillectomy
Description: Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
Study: NCT03086031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program -based vocational rehabilitation intervention
Description: The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vocational rehabilitation (controls)
Description: Treatment as usual delivered by the municipalities.
Study: NCT01463332

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: I.V injection of 10 ml normal saline
Description: Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
Study: NCT00369759

Intervention type: OTHER
Intervention: Emergency Dept. Subjects with LRI or Apnea
Description: No intervention; Epidemiological Study
Study: NCT01463332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V injection with 0.25mic/kg of dexmedetomidine
Description: Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V injection of 0.50mic/kg of dexmedetomidine
Description: Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
Study: NCT00518245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
Study: NCT00943553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine Induction Chemotherapy
Description: Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m\^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)
Study: NCT05157919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICU-Care
Description: The mobile app intervention, ICU-CARE, will consist of 3 separate education modules, each approximately 5-7 minutes in length: (Module #1) ICU orientation, (Module #2) Symptom Assessment, (Module #3) Symptom Management
Study: NCT03687905

Intervention type: DRUG
Intervention: Chloroquine
Description: group1 received chloroquine .

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Group 2 received hydroxychloroquine
Study: NCT01385332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early luteal phase
Description: We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late follicular phase -COH-
Description: We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
Study: NCT01698138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxin A
Description: 30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 transurethral injections, each of 1 ml solution containing NaCl.
Study: NCT03299179

Intervention type: DEVICE
Intervention: MRI scan
Description: Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).

Intervention type: DEVICE
Intervention: MRI scan
Description: Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).

Intervention type: DEVICE
Intervention: Physiological monitoring
Description: During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance

Intervention type: DEVICE
Intervention: Physiological monitoring
Description: During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
Study: NCT06308861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Bmg dose Group
Description: Orally, Bmg tablet single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Cmg dose Group
Description: Orally, Cmg tablet single administration